

Liquid Biopsy Early Cancer Detection Market - 2026-2035

<https://marketpublishers.com/r/L2FAF3D72AB4EN.html>

Date: July 2026

Pages: 62

Price: US\$ 3,400.00 (Single User License)

ID: L2FAF3D72AB4EN

Abstracts

Liquid Biopsy Early Cancer Detection Market reached US\$ 2.48 billion in 2025 and is expected to reach US\$ 7.85 billion by 2035, growing with a CAGR of 12.10% during the forecast period 2026-2035.

The Liquid Biopsy Early Cancer Detection Market emerges as a key focus in DataM Intelligence latest in-depth analysis, where seasoned researchers harness advanced data analytics and strategic foresight to deliver unparalleled market intelligence. This insightful report meticulously explores the competitive landscape, profiling key players and their forward-thinking innovations in product development, pricing strategies, financial metrics, and global expansion initiatives. By uncovering the driving forces, market dynamics, and disruptive trends shaping the future, this research equips industry stakeholders with the actionable insights needed to make informed decisions in an increasingly dynamic and competitive environment.

A Liquid Biopsy Early Cancer Detection Market is a data-driven software solution that collects, integrates, analyzes, and visualizes customer data across various touchpoints to generate actionable insights. These platforms help businesses understand customer behaviors, preferences, and purchasing patterns in real time, enabling personalized marketing, enhanced customer engagement, and data-driven decision-making.

By Test Type

Multi Cancer Early Detection Tests*

Single Cancer Early Detection Tests

High Risk Screening Liquid Biopsy Tests

By Biomarker Type

Circulating Tumor DNA (ctDNA) *

Cell Free DNA Methylation Biomarkers

Cell Free RNA (cfRNA)

Circulating Tumor Cells (CTCs)

Exosomes and Extracellular Vesicles

Protein Biomarkers

Multimomics Biomarker Panels

Others

By Sample Type

Blood *

Plasma

Serum

Urine

Saliva

Others

By Technology

Next Generation Sequencing (NGS) *

Polymerase Chain Reaction (PCR)

Digital PCR

Methylation Analysis

Immunoassay Based Detection

AI and Machine Learning Enabled Bioinformatics

Others

By Cancer Type

Lung Cancer *

Colorectal Cancer

Breast Cancer

Prostate Cancer

Liver Cancer

Pancreatic Cancer

Ovarian Cancer

Others

By Application

Population Screening *

High Risk Patient Screening

Complementary Screening with Conventional Methods

Recurrence Risk and Residual Disease Assessment

By End-User

Hospitals *

Discrete Manufacturing

Process Manufacturing

Cancer Specialty Centers

Diagnostic Laboratories

Academic and Research Institutes

Preventive Healthcare Programs

Others

Regional Analysis for Liquid Biopsy Early Cancer Detection Market:

North America (U.S., Canada, Mexico)

Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

South America (Colombia, Brazil, Argentina, Rest of South America)

Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

This Report Covers:

Go-to-market Strategy.

Neutral perspective on the market performance.

Development trends, competitive landscape analysis, supply side analysis, demand side analysis, year-on-year growth, competitive benchmarking, vendor identification, and other significant analysis, as well as development status.

Customized regional/country reports as per request and country level analysis.

Potential & niche segments and regions exhibiting promising growth covered.

Analysis of Market Size (historical and forecast), Total Addressable Market (TAM), Serviceable Available Market (SAM), Serviceable Obtainable Market (SOM), Market Growth, Technological Trends, Market Share, Market Dynamics, Competitive Landscape and Major Players (Innovators, Start-ups, Laggard, and Pioneer).

Research Process:

Both primary and secondary data sources have been used in the global Liquid Biopsy Early Cancer Detection Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.

Contents

1. METHODOLOGY AND SCOPE

- 1.1. Research Data
 - 1.1.1. Secondary Data
 - 1.1.2. Primary Data
 - 1.1.3. CAGR Analysis
- 1.2. Market Size Estimation Methodology
 - 1.2.1. Bottom-Up Approach
 - 1.2.2. Top-Down Approach
- 1.3. Market Breakdown & Data Triangulation
- 1.4. Research Assumptions
- 1.5. Limitations

2. DEFINITION AND OVERVIEW

- 2.1. Study Objectives
- 2.2. Market Definition
- 2.3. Market Scope
- 2.4. Stakeholder Analysis
- 2.5. Currency Considered
- 2.6. Study Period

3. EXECUTIVE SUMMARY

- 3.1. Key Takeaways
- 3.2. Top To Bottom Analysis
- 3.3. Market Share Analysis
- 3.4. Data Points from Key Primary Interviews
- 3.5. Data Points from Key Secondary Databases
- 3.6. Market Snapshot
- 3.7. Geographical Snapshot

4. DYNAMICS

- 4.1. Impacting Factors
 - 4.1.1. Drivers
 - 4.1.1.1. Clinical shift toward methylation-led and multi-omics signal enrichment

platforms

4.1.1.2. Push to detect high-mortality cancers with no routine screening pathway

4.1.1.3. Rising payer and provider interest in blood-based screening workflow

efficiency

4.1.2. Restraints

4.1.2.1. Weak reimbursement case for asymptomatic broad-population testing

4.1.2.2. Physician concern over false positives and unclear diagnostic resolution

pathways

4.1.3. Impact Analysis - Drivers and Restraints

4.1.4. Opportunity

4.1.4.1. Risk-stratified screening models for aging and high-incidence populations

4.1.4.2. Preventive health bundling through executive checkups and private wellness

ecosystems

4.1.5. Trends

4.1.5.1. Shift from mutation-only assays to methylation and fragmentomics-based

detection

4.1.5.2. Commercial movement from single-cancer screening to multi-cancer platform

positioning

4.1.6. Challenges

5. INDUSTRY ANALYSIS

5.1. Porter's Five Force Analysis

5.2. Political Factors

5.3. Social Factors 5.3.1. Rising preference for non-invasive early cancer screening

5.3.2. Growing cancer awareness and preventive health behavior 5.3.3. Aging population increasing demand for early cancer detection

5.4. Economic Factors

5.4.1. High cost burden of late-stage cancer treatment

5.4.2. Increasing healthcare spending on early diagnosis and screening

5.4.3. Expanding private and employer-funded preventive health programs

5.5. Geopolitical Factors

5.6. Supply/Value Chain Analysis

5.7. Pricing Analysis

5.8. Regulatory Analysis

5.9. Technology Landscape

5.10. Innovation & R&D Trends

5.11. Sustainability and ESG Analysis

5.12. Risk Avoidance Model

- 5.13. Go-To-Market Strategy
- 5.14. BCG Matrix
- 5.15. Business Models Analysis
- 5.16. Demand-Supply Gap
- 5.17. Risk Mitigation Framework
- 5.18. Compliance Roadmap
- 5.19. Strategic Implications
- 5.20. Emerging Opportunities
- 5.21. Adoption Trends
- 5.22. Disruption Analysis
- 5.23. DMI Opinion

6. BY TEST TYPE

- 6.1. Introduction
 - 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
 - 6.1.2. Market Attractiveness Index, By Test Type
- 6.2. Multi Cancer Early Detection Tests*
 - 6.2.1. Introduction
 - 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 6.3. Single Cancer Early Detection Tests
- 6.4. High Risk Screening Liquid Biopsy Tests

7. BY BIOMARKER TYPE

- 7.1. Introduction
 - 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Biomarker Type
 - 7.1.2. Market Attractiveness Index, By Biomarker Type
- 7.2. Circulating Tumor DNA (ctDNA) *
 - 7.2.1. Introduction
 - 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 7.3. Cell Free DNA Methylation Biomarkers
- 7.4. Cell Free RNA (cfRNA)
- 7.5. Circulating Tumor Cells (CTCs)
- 7.6. Exosomes and Extracellular Vesicles
- 7.7. Protein Biomarkers
- 7.8. Multiomics Biomarker Panels
- 7.9. Others

8. BY SAMPLE TYPE

8.1. Introduction

8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sample Type

8.1.2. Market Attractiveness Index, By Sample Type

8.2. Blood *

8.2.1. Introduction

8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)

8.3. Plasma

8.4. Serum

8.5. Urine

8.6. Saliva

8.7. Others

9. BY TECHNOLOGY

9.1. Introduction

9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology

9.1.2. Market Attractiveness Index, By Technology

9.2. Next Generation Sequencing (NGS) *

9.2.1. Introduction

9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)

9.3. Polymerase Chain Reaction (PCR)

9.4. Digital PCR

9.5. Methylation Analysis

9.6. Immunoassay Based Detection

9.7. AI and Machine Learning Enabled Bioinformatics

9.8. Others

10. BY CANCER TYPE

10.1. Introduction

10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type

10.1.2. Market Attractiveness Index, By Cancer Type

10.2. Lung Cancer *

10.2.1. Introduction

10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)

10.3. Colorectal Cancer

10.4. Breast Cancer

- 10.5. Prostate Cancer
- 10.6. Liver Cancer
- 10.7. Pancreatic Cancer
- 10.8. Ovarian Cancer
- 10.9. Others

11. BY APPLICATION

- 11.1. Introduction
 - 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
 - 11.1.2. Market Attractiveness Index, By Application
- 11.2. Population Screening *
 - 11.2.1. Introduction
 - 11.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
 - 11.2.3. High Risk Patient Screening
 - 11.2.4. Complementary Screening with Conventional Methods
 - 11.2.5. Recurrence Risk and Residual Disease Assessment

12. BY END-USER

- 12.1. Introduction
 - 12.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
 - 12.1.2. Market Attractiveness Index, By End-User
- 12.2. Hospitals *
 - 12.2.1. Introduction
 - 12.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
 - 12.2.3. Discrete Manufacturing
 - 12.2.4. Process Manufacturing
- 12.3. Cancer Specialty Centers
- 12.4. Diagnostic Laboratories
- 12.5. Academic and Research Institutes
- 12.6. Preventive Healthcare Programs
- 12.7. Others

13. BY REGION

- 13.1. Introduction
 - 13.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
 - 13.1.2. Market Attractiveness Index, By Region

13.2. North America*

13.2.1. Introduction

13.2.2. Key Region-Specific Dynamics

13.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type

13.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Biomarker Type

13.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sample Type

13.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology

13.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type

13.2.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application

13.2.9. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

14. MARKET SIZE ANALYSIS AND Y-O-Y GROWTH ANALYSIS (%), BY COUNTRY

14.1. U.S.

14.1.1. Canada

14.1.1.1. Mexico

14.2. Europe

14.2.1. Germany

14.2.1.1. UK

14.2.1.2. France

14.2.1.3. Russia

14.2.1.4. Spain

14.2.1.5. Italy

14.2.1.6. Poland

14.2.1.7. Rest of Europe

14.3. Latin America

14.3.1. Brazil

14.3.1.1. Argentina

14.3.1.2. Rest of Latin America

14.4. Asia-Pacific

14.4.1. China

14.4.1.1. India

14.4.1.2. Japan

14.4.1.3. Australia

14.4.1.4. South Korea

14.4.1.5. Indonesia

14.4.1.6. Malaysia

14.4.1.7. Rest of Asia-Pacific

14.5. Middle East and Africa

14.5.1. UAE

14.5.1.1. Saudi Arabia

14.5.1.2. South Africa

14.5.1.3. Israel

14.5.1.4. Turkiye

14.5.1.5. Rest of Middle East and Africa

15. COMPETITIVE LANDSCAPE

15.1. Competitive Scenario

15.2. Market Share Analysis - Global

15.3. Market Share Analysis - North America

15.4. Market Share Analysis - Europe

15.5. Market Share Analysis - Asia-Pacific

15.6. Mergers and Acquisitions Analysis

15.7. Partner Identification Analysis

15.8. Investment & Funding Landscape

15.9. Strategic Alliances & Innovation Pipeline

16. COMPANY PROFILES

16.1. GRAIL*

16.1.1. Company Overview

16.1.2. Product Portfolio and Description

16.1.3. Revenue Analysis

16.1.4. Pricing Analysis

16.1.5. SWOT Analysis

16.1.6. Recent Developments

16.1.6.1. Major Deals

16.1.6.2. M&A

16.1.6.3. Collaboration

16.1.6.4. Acquisition

16.1.6.5. Joint Ventures

16.1.6.6. Innovations

16.1.7. Recent News

16.1.7.1. Events

16.1.7.2. Conferences

16.1.7.3. Symposiums

16.1.7.4. Webinars

- 16.2. Guardant Health
- 16.3. Exact Sciences Corporation
- 16.4. Freenome Holdings, Inc.
- 16.5. SeekIn Inc.
- 16.6. Singlera Genomics Inc.
- 16.7. Harbinger Health
- 16.8. Elypta
- 16.9. AnchorDx
- 16.10. Lucence Health Inc.
- 16.11. Burning Rock Biotech Limited
- 16.12. Natera, Inc.
- 16.13. Oxford BioDynamics Plc
- 16.14. PredOmix
- 16.15. Genecast Group Inc.
- 16.16. CORE Diagnostics
- 16.17. DELFI Diagnostics
- 16.18. ClearNote Health
- 16.19. ANPAC Bio-Medical Science Co., Ltd.
- 16.20. 20/20 BioLabs, Inc. (LIST NOT EXHAUSTIVE)

17. APPENDIX

- 17.1. About Us and Services
- 17.2. Contact Us

I would like to order

Product name: Liquid Biopsy Early Cancer Detection Market - 2026-2035

Product link: <https://marketpublishers.com/r/L2FAF3D72AB4EN.html>

Price: US\$ 3,400.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/L2FAF3D72AB4EN.html>